1 Abstract
Since its discovery, more than 37 million people have been infected by SARS-CoV-2 with deaths around 1 million worldwide. The prevalence is not known because infected individuals may be asymptomatic. In addition, the use of specific diagnostic tests is not always conclusive, raising doubts about the etiology of the disease.
The best diagnostic method and the ideal time of collection remains the subject of study. The gold standard for diagnosing COVID 19 is the RT PCR molecular test, usually using an oropharynx and nasopharynx swab. Its sensitivity is 70% and drops significantly after the second week of symptoms. Serological tests, in turn, have increased sensitivity after 14 days, and can contribute to the diagnosis when SARS-CoV-2 infection is suspected, even with negative RT PCR.
Our study showed sensitivity and specificity of 100% of the serological test (ELISA method) for cases of viral pneumonia caused by the new coronavirus, suggesting that this test could assist in the diagnosis of pulmonary interstitial changes that have not yet been etiologically clarified. We found a greater immune response in men, regardless of the severity of symptoms. The greater the severity, the higher the levels of IgA and IgG, mainly found in patients with multilobar impairment and in need for oxygen. We concluded that the serological test collected around 30 days after the onset of symptoms is the best diagnostic tool in the convalescence phase, not only for epidemiological purposes, but also for the etiological clarification of pulmonary changes that have not yet been diagnosed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No Fundind was received by the author to this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the data necessary to prove the research is available The research project was submitted for approval by the Human Research Ethics Committee of the Hospital Beneficencia Portuguesa de Sao Paulo, the institution where the work was carried out. There was unanimous approval for its elaboration, without additional objections or considerations, fulfilling all the established and requested ethical criteria. The final opinion of the internal body follows below, as well as the names of the members who are part of it. Final Considerations at the discretion of the Research Ethics Committee In view of the above, the Portuguese Charity Research Ethics Committee, in accordance with the attributions defined in CNS Resolution No. 466/2012 and subsequent ones, is manifested by the Approval of Project, as proposed to start the Research. Research Ethics Committee members Alexandra Paola Zandonai (Non-medical member) Bruno Daniel Alves do Amaral (Non-medical member) Bruno Papelbaum (medical member) Camilla do Rosario Nicolino Chiorino (Non-medical member) Cecilia Kauffman Rutenberg Fede(medical member) Cristiane Almeida Hanashiro. (Non-medical member) Daniani Baldani da Costa Wilson (Non-medical member) Danielle Leao Cordeiro de Farias (medical member) Dino Martini Filho (medical member) Erika Akemi Tsujiguchi Bernardi (Non-medical member) Fernanda Nascimento Faro (medical member) Graziela Zibetti Dal Molin (medical member) Hugo Abensur (Coordinator) Ligia Maria Coscrato Junqueira (Non-medical member) Maria Conceicao Silva Amaral (Non-medical member) Rodrigo Noronha Campos (Vice coordinator) Tereza Luiza Bellincanta Fakhouri (medical member) Weruska Davi Barrios(Non-medical member)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is available to answer any questions
